Chemours (NYSE:CC) Stock Rating Upgraded by Zacks Research

Chemours (NYSE:CC) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports. Zacks Research also issued estimates for Chemours’ Q1 2027 earnings at $0.39 EPS, Q3 2027 earnings at $0.56 EPS, Q4 2027 earnings at $0.53 EPS, Q2 2028 earnings at $0.61 EPS and FY2028 earnings at $2.38 EPS.

A number of other brokerages also recently weighed in on CC. Alembic Global Advisors reaffirmed an “overweight” rating and issued a $30.00 target price on shares of Chemours in a research note on Wednesday, May 13th. Truist Financial increased their price target on shares of Chemours from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. JPMorgan Chase & Co. raised their price target on shares of Chemours from $17.00 to $22.00 and gave the company a “neutral” rating in a report on Thursday, May 21st. Weiss Ratings restated a “sell (d)” rating on shares of Chemours in a research report on Friday, July 17th. Finally, UBS Group upped their price objective on Chemours from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Chemours currently has an average rating of “Moderate Buy” and an average target price of $24.10.

Chemours Stock Up 1.8%

Shares of CC stock opened at $18.24 on Tuesday. The stock has a market cap of $2.74 billion, a P/E ratio of -6.91 and a beta of 1.41. Chemours has a one year low of $10.44 and a one year high of $28.67. The stock has a fifty day moving average price of $20.61 and a 200 day moving average price of $19.85. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.82 and a quick ratio of 0.87.

Chemours (NYSE:CC) last announced its quarterly earnings results on Tuesday, May 5th. The specialty chemicals company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.10. Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. The firm had revenue of $1.38 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same quarter in the previous year, the firm posted $0.13 EPS. The business’s revenue for the quarter was up 1.0% on a year-over-year basis. Analysts predict that Chemours will post 1.18 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Parallel Advisors LLC grew its holdings in Chemours by 10.9% during the 1st quarter. Parallel Advisors LLC now owns 5,366 shares of the specialty chemicals company’s stock worth $118,000 after acquiring an additional 527 shares during the period. Oregon Public Employees Retirement Fund lifted its stake in shares of Chemours by 1.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 34,300 shares of the specialty chemicals company’s stock valued at $404,000 after purchasing an additional 600 shares during the period. PFG Investments LLC boosted its position in shares of Chemours by 7.6% in the 4th quarter. PFG Investments LLC now owns 12,494 shares of the specialty chemicals company’s stock worth $147,000 after purchasing an additional 883 shares during the last quarter. State of Alaska Department of Revenue grew its stake in shares of Chemours by 1.2% during the fourth quarter. State of Alaska Department of Revenue now owns 76,257 shares of the specialty chemicals company’s stock worth $899,000 after purchasing an additional 932 shares during the period. Finally, Man Group plc grew its stake in shares of Chemours by 0.4% during the second quarter. Man Group plc now owns 271,108 shares of the specialty chemicals company’s stock worth $3,104,000 after purchasing an additional 979 shares during the period. Institutional investors own 76.26% of the company’s stock.

About Chemours

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.